The application of the palliative prognostic index, charlson comorbidity index, and Glasgow prognostic score in predicting the life expectancy of patients with hematologic malignancies under palliative care

BMC Palliative Care

Research Article

Kun-Yun Yeh¹  Pei-Hung Chang¹  Hung-Ming Wang²  Yu-Shin Hung²  Hung Chang²  Chen-Yi Kao²  Wen-Chi Chou²  Po-Nan Wang² 

[1] Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital Keelung branch, Keelung, Taiwan;Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital Linkou branch, and School of Medicine, Chang Gung University, No. 5 Fuxing Street, Guishan Township, Taoyuan, Taiwan;

关键词: Palliative prognostic index;    Charlson comorbidity index;    Glasgow prognostic score;    Prognostication;    Hematologic malignancy;    Palliative care;   

DOI  :  10.1186/s12904-015-0011-5

 received in 2014-09-05, accepted in 2015-03-11,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundThe clinical course for hematologic malignancy varies widely and no prognostic tool is available for patients with a hematologic malignancy under palliative care. To assess the application of the Palliative Prognostic Index (PPI), Charlson Comorbidity Index (CCI), and Glasgow Prognostic Score (GPS) as prognostic tools in patients with hematologic malignancies under palliative care.MethodsWe included 217 patients with pathologically proven hematologic malignancies under palliative care consultation service (PCCS) between January 2006 and December 2012 at a single medical center in Taiwan. Patients were categorized into subgroups by PPI, CCI, and GPS for survival analysis.ResultsThe median survival was 16 days (interquartile range, 4–47.5 days) for all patients and 204 patients (94%) died within 180 days after PCCS. There was a significant difference in survival among patients categorized using the PPI (median survival 49, 15, and 7 days in patients categorized into a good, intermittent, and poor prognostic group, respectively) and the GPS (median survival 66 and 13 days for GPS 0 and 1, respectively). There was no difference in survival between patients with a GPS score of 0 versus 2, or a CCI score of 0 versus ≥1. The survival time was significantly discriminated after stratifying patients with a good PPI score based on the CCI (median survival 102 and 41 days in patients with a CCI score of 0 and ≥1, respectively) from those with a poor PPI score by using the GPS (median survival 47 and 7 days in patients with GPS scores of 0 and 1–2, respectively).ConclusionsPPI is a useful prognosticator of life expectancy in terminally ill patients under palliative care for a hematologic malignancy. Concurrent use of the GPS and CCI improved the accuracy of prognostication using the PPI.

【 授权许可】

Unknown   
© Chou et al.; licensee BioMed Central. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.